9 results on '"Karampatou, A"'
Search Results
2. Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis
- Author
-
Villa, Erica, Cammà, Calogero, Marietta, Marco, Luongo, Monica, Critelli, Rosina, Colopi, Stefano, Tata, Cristina, Zecchini, Ramona, Gitto, Stefano, Petta, Salvatore, Lei, Barbara, Bernabucci, Veronica, Vukotic, Ranka, De Maria, Nicola, Schepis, Filippo, Karampatou, Aimilia, Caporali, Cristian, Simoni, Luisa, Del Buono, Mariagrazia, Zambotto, Beatrice, Turola, Elena, Fornaciari, Giovanni, Schianchi, Susanna, Ferrari, Anna, and Valla, Dominique
- Published
- 2012
- Full Text
- View/download PDF
3. Reproductive status is associated with the severity of fibrosis in women with hepatitis C.
- Author
-
Erica Villa, Ranka Vukotic, Calogero Cammà, Salvatore Petta, Alfredo Di Leo, Stefano Gitto, Elena Turola, Aimilia Karampatou, Luisa Losi, Veronica Bernabucci, Annamaria Cenci, Simonetta Tagliavini, Enrica Baraldi, Nicola De Maria, Roberta Gelmini, Elena Bertolini, Maria Rendina, and Antonio Francavilla
- Subjects
Medicine ,Science - Abstract
Chronic hepatitis C is the main cause of death in patients with end-stage liver disease. Prognosis depends on the increase of fibrosis, whose progression is twice as rapid in men as in women. Aim of the study was to evaluate the effects of reproductive stage on fibrosis severity in women and to compare these findings with age-matched men.A retrospective study of 710 consecutive patients with biopsy-proven chronic hepatitis C was conducted, using data from a clinical database of two tertiary Italian care centers. Four age-matched groups of men served as controls. Data about demographics, biochemistry, liver biopsy and ultrasonography were analyzed. Contributing factors were assessed by multivariate logistic regression analysis.Liver fibrosis was more advanced in the early menopausal than in the fully reproductive (P
- Published
- 2012
- Full Text
- View/download PDF
4. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C
- Author
-
Villa, E., Cammà, C., Di Leo, A., Karampatou, A., Enea, M., Gitto, S., Bernabucci, V., Losi, L., De Maria, N., Lei, B., Ferrari, A., Vukotic, R., Vignoli, P., Rendina, M., and Francavilla, A.
- Published
- 2012
- Full Text
- View/download PDF
5. Pharmacotherapy of Painful Diabetic Neuropathy: A Clinical Update.
- Author
-
Fernandez James, Cornelius, Tripathi, Shiva, Karampatou, Kyriaki, Gladston, Divya V., and Pappachan, Joseph M.
- Subjects
DRUG therapy ,DIABETIC neuropathies ,DIABETES ,OPIOIDS ,PUBLIC health - Abstract
The rising prevalence of diabetes mellitus (DM) leads on to an increase in chronic diabetic complications. Diabetic peripheral neuropathies (DPNs) are common chronic complications of diabetes. Distal symmetric polyneuropathy is the most prevalent form. Most patients with DPN will remain pain-free; however, painful DPN (PDPN) occurs in 6-34% of all DM patients and is associated with reduced health-related-quality-of-life and substantial economic burden. Symptomatic treatment of PDPN and diabetic autonomic neuropathy is the key treatment goals. Using certain patient related characteristics, subjects with PDPN can be stratified and assigned targeted therapies to produce better pain outcomes. The aim of this review is to discuss the various pathogenetic mechanisms of DPN with special reference to the mechanisms leading to PDPN and the various pharmacological and non-pharmacological therapies available for its management. Recommended pharmacological therapies include anticonvulsants, antidepressants, opioid analgesics, and topical medications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV.
- Author
-
Karampatou, Aimilia, Critelli, Rosina Maria, Bernabucci, Veronica, D'Ambrosio, Federica, Bristot, Laura, Turco, Laura, Villa, Erica, Bruno, Savino, Han, Xue, Kondili, Loreta A., Rosato, Stefano, Vella, Stefano, Taliani, Gloria, Ciancio, Alessia, Troshina, Giulia, Morisco, Filomena, Guarino, Maria, Baraldi, Enrica, Tagliavini, Simonetta, and Trenti, Tommaso
- Subjects
- *
HEPATITIS C diagnosis , *OVARIAN diseases , *HEPATITIS C treatment , *MISCARRIAGE , *WOMEN'S health , *DIAGNOSIS , *THERAPEUTICS - Abstract
Background & Aims Premenopausal women who are HCV positive (HCV+) have failing ovarian function, which is likely to impact their fertility. Thus, we investigated the reproductive history, risk of infertility, and pregnancy outcomes in women of childbearing age who were HCV+. Methods Three different groups were studied: (1) Clinical cohort: 100 women who were HCV+ and also had chronic liver disease (CLD), age matched with 50 women who were HBV+ with CLD and with 100 healthy women; all women were consecutively observed in three gastroenterology units in hospitals in Italy; (2) 1,998 women who were HCV+ and enrolled in the Italian Platform for the Study of Viral Hepatitis Therapies (PITER); (3) 6,085 women, who were mono-infected with HCV, and 20,415 women, who were HCV−, from a large de-identified insurance database from the USA. Measurements: total fertility rate (TFR) defined as the average number of children that a woman would bear during her lifetime. To define the reproductive stage of each participant, levels of anti-Müllerian hormone (AMH) and 17β-estradiol were measured. Results Clinical cohort: women who were either HCV+ or HBV+ had similar CLD severity and age at first pregnancy. Based on a multivariate analysis, women who were HCV+ had a higher risk of miscarriage than those who were HBV+ (odds ratio [OR] 6,905; 95% CI 1.771–26.926). Among women who were HCV+, incidence of miscarriage was correlated with median AMH level (1.0 ng/ml). Achieving a sustained virologic response (SVR) after antiviral treatment reduced the risk of miscarriage (OR 0.255; 95% CI 0.090–0.723). In the PITER-HCV cohort, miscarriage occurred in 42.0% of women (44.6% had multiple miscarriages). TFR for women who were HCV+ and between 15 and 49 years of age was 0.7 vs. 1.37 of Italian population of the same age range. In the US cohort: compared with women who were HCV−, women who were HCV+ positive were significantly more likely to have infertility (OR 2.439; 95% CI 2.130–2.794), premature birth (OR 1.34; 95% CI 1.060–1.690), gestational diabetes (OR 1.24; 95% CI 1.020–1.510), and pre-eclampsia (OR 1.206; 95% CI 0.935–1.556), and were less likely to have a live birth (OR 0.754; 95% CI 0.622–0.913). Conclusions Ovarian senescence in women of childbearing age who are HCV+ is associated with a lower chance of live birth, greater risk of infertility, gestational diabetes, pre-eclampsia and miscarriage. Such risks could be positively influenced by successful HCV cure. Lay summary Most new cases of HCV infection are among people who inject drugs, many of whom are young women in their childbearing years. Women of reproductive age who are HCV+ display markers of ovarian senescence. This is associated with an increased burden in terms of infertility and adverse pregnancy outcomes, including stillbirth, miscarriage, fewer live births, and gestational diabetes. Early viral suppression with therapy is likely to mitigate these risks. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study.
- Author
-
Villa, Erica, Critelli, Rosina, Lei, Barbara, Marzocchi, Guido, Cammà, Calogero, Giannelli, Gianluigi, Pontisso, Patrizia, Cabibbo, Giuseppe, Enea, Marco, Colopi, Stefano, Caporali, Cristian, Pollicino, Teresa, Milosa, Fabiola, Karampatou, Aimilia, Todesca, Paola, Bertolini, Elena, Maccio, Livia, Martinez-Chantar, Maria Luz, Turola, Elena, and Buono, Mariagrazia Del
- Subjects
LIVER cancer ,LIVER tumors ,CIRRHOSIS of the liver ,HETEROGENEITY ,TREATMENT of cirrhosis of the liver ,DIAGNOSIS - Abstract
Objective The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results of a genome-wide highthroughput analysis into a tool that accurately predicts at presentation tumour growth and survival of patients with HCC. Design Ultrasound surveillance identified HCC in 78 (training set) and 54 (validation set) consecutive patients with cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine tumour volumes (V0 and V1) and calculate HCC doubling time. Baseline-paired HCC and surrounding tissue biopsies for microarray study (Agilent Whole Human Genome Oligo Microarrays) were also obtained. Predictors of survival were assessed by multivariate Cox model. Results Calculated tumour doubling times ranged from 30 to 621 days (mean, 107±91 days; median, 83 days) and were divided into quartiles: ⩽53 days (n=19), 54-82 days (n=20), 83-110 days (n=20) and ⩾111 days (n=19). Median survival according to doubling time was significantly lower for the first quartile versus the others (11 vs 41 months, 42, and 47 months, respectively) (p<0.0001). A five-gene transcriptomic hepatic signature including angiopoietin-2 (ANGPT2), delta-like ligand 4 (DLL4), neuropilin (NRP)/tolloid (TLL)-like 2 (NETO2), endothelial cell-specific molecule-1 (ESM1), and nuclear receptor subfamily 4, group A, member 1 (NR4A1) was found to accurately identify rapidly growing HCCs of the first quartile (ROC AUC: 0.961; 95% CI 0.919 to 1.000; p<0.0001) and to be an independent factor for mortality (HR: 3.987; 95% CI 1.941 to 8.193, p<0.0001). Conclusions The hepatic five-gene signature was able to predict HCC growth in individual patient and the consequent risk of death. This implies a role of this molecular tool in the future therapeutic management of patients with HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Reproductive Status Is Associated with the Severity of Fibrosis in Women with Hepatitis C.
- Author
-
Villa, Erica, Vukotic, Ranka, Cammà, Calogero, Petta, Salvatore, Di Leo, Alfredo, Gitto, Stefano, Turola, Elena, Karampatou, Aimilia, Losi, Luisa, Bernabucci, Veronica, Cenci, Annamaria, Tagliavini, Simonetta, Baraldi, Enrica, De Maria, Nicola, Gelmini, Roberta, Bertolini, Elena, Rendina, Maria, and Francavilla, Antonio
- Subjects
CHRONIC hepatitis C ,LIVER diseases ,CYSTIC fibrosis ,DISEASES in men ,DISEASES in women - Abstract
Introduction: Chronic hepatitis C is the main cause of death in patients with end-stage liver disease. Prognosis depends on the increase of fibrosis, whose progression is twice as rapid in men as in women. Aim of the study was to evaluate the effects of reproductive stage on fibrosis severity in women and to compare these findings with age-matched men. Materials and Methods: A retrospective study of 710 consecutive patients with biopsy-proven chronic hepatitis C was conducted, using data from a clinical database of two tertiary Italian care centers. Four age-matched groups of men served as controls. Data about demographics, biochemistry, liver biopsy and ultrasonography were analyzed. Contributing factors were assessed by multivariate logistic regression analysis. Results: Liver fibrosis was more advanced in the early menopausal than in the fully reproductive (P<0.0001) or premenopausal (P = 0.042) group. Late menopausal women had higher liver fibrosis compared with the other groups (fully reproductive, P<0.0001; premenopausal, P =<0.0001; early menopausal, P = 0.052). Multivariate analyses showed that male sex was independently associated with more severe fibrosis in the groups corresponding to premenopausal (P = 0.048) and early menopausal (P = 0.004) but not late menopausal pairs. In women, estradiol/testosterone ratio decreased markedly in early (vs. reproductive age: P = 0.002 and vs. premenopausal: P<0.0001) and late menopause (vs. reproductive age: P = 0.001; vs. premenopausal: P<0.0001). In men age-matched with menopausal women, estradiol/testosterone ratio instead increased (reproductive age group vs. early: P = 0.002 and vs. late M: P = 0.001). Conclusions: The severity of fibrosis in women worsens in parallel with increasing estrogen deprivation and estradiol/ testosterone ratio decrease. Our data provide evidence why fibrosis progression is discontinuous in women and more linear and severe in men, in whom aging-associated estradiol/testosterone ratio increase occurs too late to noticeably influence the inflammatory process leading to fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
9. Early Menopause Is Associated With Lack of Response to Antiviral Therapy in Women With Chronic Hepatitis C.
- Author
-
Villa, Erica, Karampatou, Aimilia, Cammà, Calogero, Di Leo, Alfredo, Luongo, Monica, Ferrari, Anna, Petta, Salvatore, Losi, Luisa, Taliani, Gloria, Trande, Paolo, Lei, Barbara, Graziosi, Amalia, Bernabucci, Veronica, Critelli, Rosina, Pazienza, Paola, Rendina, Maria, Antonelli, Alessandro, and Francavilla, Antonio
- Subjects
HEPATITIS C treatment ,ANTIVIRAL agents ,MENOPAUSE ,CONFIDENCE intervals ,TUMOR necrosis factors ,INTERLEUKINS ,LIVER diseases ,PATIENTS - Abstract
Background & Aims: Chronic hepatitis C (CHC) and liver fibrosis progress more rapidly in men and menopausal women than in women of reproductive age. We investigated the associations among menopause, sustained virologic response (SVR), and liver damage in patients with CHC. Methods: We performed a prospective study of 1000 consecutive, treatment-naïve patients 18 years of age and older with compensated liver disease from CHC. Liver biopsy samples were analyzed (for fibrosis, inflammation, and steatosis) before patients received standard antiviral therapy. From women (n = 442), we collected data on the presence, type, and timing of menopause; associated hormone and metabolic features; serum levels of interleukin-6; and hepatic tumor necrosis factor (TNF)-α. Results: Postmenopausal women achieved SVRs less frequently than women of reproductive age (46.0% vs 67.5%; P < .0001) but as frequently as men (51.1%; P = .283). By multivariate regression analysis, independent significant predictors for women to not achieve an SVR were early menopause (odds ratio [OR], 8.055; 95% confidence interval [CI], 1.834–25.350), levels of γ-glutamyl transpeptidase (OR, 2.165; 95% CI, 1.364–3.436), infection with hepatitis C virus genotype 1 or 4 (OR, 3.861; 95% CI, 2.433–6.134), and cholesterol levels (OR, 0.985; 95% CI, 0.971–0.998). Early menopause was the only independent factor that predicted lack of an SVR among women with genotype 1 hepatitis C virus infection (OR, 3.933; 95% CI, 1.274–12.142). Baseline levels of liver inflammation, fibrosis, steatosis, serum interleukin-6 (P = .04), and hepatic TNF-α (P = .007) were significantly higher among postmenopausal women than women of reproductive age. Conclusions: Among women with CHC, early menopause was associated with a low likelihood of SVR, probably because of inflammatory factors that change at menopause. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.